{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:17:01Z","timestamp":1770722221021,"version":"3.49.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Reduced antituberculosis drug concentrations may contribute to unfavorable treatment outcomes among HIV-infected patients with more advanced immune suppression, and few studies have evaluated pharmacokinetics of the first-line antituberculosis drugs in such patients given fixed-dose combination tablets according to international guidelines using weight bands. In this study, pharmacokinetics were evaluated in 60 patients on 4 occasions during the first month of antituberculosis therapy. Multilevel linear mixed-effects regression analysis was used to examine the effects of age, sex, weight, drug dose\/kilogram, CD4<jats:sup>+<\/jats:sup>lymphocyte count, treatment schedule (5 versus 7 days\/week), and concurrent antiretrovirals (efavirenz plus lamivudine plus zidovudine) on the area under the concentration-time curve from 0 to 12 h (AUC<jats:sub>0-12<\/jats:sub>) of the respective antituberculosis drugs and to compare AUC<jats:sub>0-12<\/jats:sub>s at day 8, day 15, and day 29 with the day 1 AUC<jats:sub>0-12<\/jats:sub>. Median (range) age, weight, and CD4<jats:sup>+<\/jats:sup>lymphocyte count were 32 (18 to 47) years, 55.2 (34.4 to 98.7) kg, and 252 (12 to 500)\/\u03bcl. For every 10-kg increase in body weight, the predicted day 29 AUC<jats:sub>0-12<\/jats:sub>increased by 14.1% (95% confidence interval [CI], 7.5, 20.8), 14.1% (95% CI, \u22120.7, 31.1), 6.1% (95% CI, 2.7, 9.6) and 6.0% (95% CI, 0.8, 11.3) for rifampin, isoniazid, pyrazinamide, and ethambutol, respectively. Males had day 29 AUC<jats:sub>0-12<\/jats:sub>s 19.3% (95% CI, 3.6, 35.1) and 14.0% (95% CI, 5.6, 22.4) lower than females for rifampin and pyrazinamide, respectively. Level of immune suppression and concomitant antiretrovirals had little effect on the concentrations of the antituberculosis agents. As they had reduced drug concentrations, it is important to review treatment responses in patients in the lower weight bands and males to inform future treatment guidelines, and revision of doses in these patients should be considered.<\/jats:p>","DOI":"10.1128\/aac.05526-11","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T04:50:36Z","timestamp":1331614236000},"page":"3232-3238","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":94,"title":["Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines"],"prefix":"10.1128","volume":"56","author":[{"given":"Helen","family":"McIlleron","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Rustomjee","sequence":"additional","affiliation":[{"name":"TB Research Unit: Clinical and Biomedical, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnaz","family":"Vahedi","sequence":"additional","affiliation":[{"name":"Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuli","family":"Mthiyane","sequence":"additional","affiliation":[{"name":"TB Research Unit: Clinical and Biomedical, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Connolly","sequence":"additional","affiliation":[{"name":"TB Research Unit: Clinical and Biomedical, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasima","family":"Rida","sequence":"additional","affiliation":[{"name":"1129 N. Illinois St. Arlington, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Pym","sequence":"additional","affiliation":[{"name":"TB Research Unit: Clinical and Biomedical, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Onyebujoh","sequence":"additional","affiliation":[{"name":"Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman W","year":"2006","unstructured":"BurmanW. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350\u2013356.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/514513"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/40.2.113"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9609132"},{"key":"e_1_3_2_11_2","first-page":"1331","article-title":"Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report","author":"East African-British Medical Research and Councils","year":"1973","unstructured":"East African-British Medical Research and Councils. 1973. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet i:1331\u20131338.","journal-title":"Lancet"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1378\/chest.76.6_Supplement.785","article-title":"The chemotherapy of pulmonary tuberculosis: a review","volume":"76","author":"Fox W","year":"1979","unstructured":"FoxW. 1979. The chemotherapy of pulmonary tuberculosis: a review. Chest 76:785\u2013796.","journal-title":"Chest"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/510247"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4473-4475.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0140-6736(93)91474-Z","article-title":"Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya","volume":"342","author":"Hawken M","year":"1993","unstructured":"HawkenM. 1993. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 342:332\u2013337.","journal-title":"Lancet"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2334-10-258","article-title":"Factors associated with mortality in patients with tuberculosis","volume":"10","author":"Horne DJ","year":"2010","unstructured":"HorneDJ. 2010. Factors associated with mortality in patients with tuberculosis. BMC Infect. Dis. 10:258.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17141-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0361-090X(02)00010-7","article-title":"Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention","volume":"26","author":"Loktionov A","year":"2002","unstructured":"LoktionovA. 2002. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect. Prev. 26:15\u201322.","journal-title":"Cancer Detect. Prev."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm393"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1170-1177.2006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/jech.2008.077560","article-title":"Tuberculosis recurrence and its associated risk factors among successfully treated patients","volume":"63","author":"Millet JP","year":"2009","unstructured":"MilletJP. 2009. Tuberculosis recurrence and its associated risk factors among successfully treated patients. J. Epidemiol. Community Health 63:799\u2013804.","journal-title":"J. Epidemiol. Community Health"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426040-00005"},{"key":"e_1_3_2_23_2","first-page":"973","article-title":"Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia","volume":"14","author":"Mu\u00f1oz-Sellart M","year":"2010","unstructured":"Mu\u00f1oz-SellartM CuevasLE TumatoM MeridY YassinMA. 2010. Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. Int. J. Tuberc. Lung Dis. 14:973\u2013979.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","article-title":"Treatment outcomes of patients with HIV and tuberculosis","volume":"175","author":"Nahid P","year":"2007","unstructured":"NahidP. 2007. Treatment outcomes of patients with HIV and tuberculosis. Am. J. Respir. Crit. Care Med. 175:1199\u20131206.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/381675","article-title":"Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use","volume":"38","author":"Nettles RE","year":"2004","unstructured":"NettlesRE. 2004. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin. Infect. Dis. 38:731\u2013736.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/00031305.1992.10475842","article-title":"A note on the delta method","volume":"46","author":"Oehlert GW","year":"1992","unstructured":"OehlertGW. 1992. A note on the delta method. Am. Stat. 46:27\u201329.","journal-title":"Am. Stat."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320518"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000901"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/498024"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02377.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440230105014"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.822-823.2006"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-4-199708150-00006"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.052175"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.5588\/09640569513002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium","volume":"353","author":"Vernon A","year":"1999","unstructured":"VernonA BurmanW BenatorD KhanA BozemanL. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843\u20131847.","journal-title":"Lancet"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":"Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity","volume":"12","author":"Walker K","year":"2009","unstructured":"WalkerK. 2009. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B Crit. Rev. 12:440\u2013472.","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"e_1_3_2_40_2","volume-title":"Treatment of tuberculosis: guidelines for national programmes","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. WHO\/CDS\/TB\/2003.313. World Health Organization, Geneva, Switzerland.","edition":"3"},{"key":"e_1_3_2_41_2","first-page":"1360","article-title":"Pharmacokinetics of ethambutol in children and adults with tuberculosis","volume":"8","author":"Zhu M","year":"2004","unstructured":"ZhuM. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1360\u20131367.","journal-title":"Int. J. Tuberc. Lung Dis."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05526-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05526-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:01:48Z","timestamp":1713693708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05526-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1128\/AAC.05526-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05526-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2011-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}